214 related articles for article (PubMed ID: 35409355)
1. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review.
Iannantuono GM; Riondino S; Sganga S; Roselli M; Torino F
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409355
[TBL] [Abstract][Full Text] [Related]
2.
Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
[TBL] [Abstract][Full Text] [Related]
3. ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review.
Yang J; Dong L; Du H; Li XB; Liang YX; Liu GR
Diagn Pathol; 2019 Oct; 14(1):112. PubMed ID: 31627758
[TBL] [Abstract][Full Text] [Related]
4. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
5. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects.
Kuroda N; Sugawara E; Kusano H; Yuba Y; Yorita K; Takeuchi K
Pol J Pathol; 2018; 69(2):109-113. PubMed ID: 30351856
[TBL] [Abstract][Full Text] [Related]
6. Identification of anaplastic lymphoma kinase fusion in clear cell renal carcinoma (ALK-tRCC): a precision oncology medicine case report.
Varchetta V; Campanella C; Rossi M; Verzaro R; Vitale M; Soda G; Mancuso A
Recenti Prog Med; 2021 Jan; 112(1):14e-15e. PubMed ID: 33512368
[TBL] [Abstract][Full Text] [Related]
7. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
Kathuria-Prakash N; Lopez LP; Raman S; Ye H; Anaokar J; Sisk A; Pantuck AJ; Drakaki A
JCO Precis Oncol; 2024 Jun; 8():e2400154. PubMed ID: 38885453
[TBL] [Abstract][Full Text] [Related]
8. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
[TBL] [Abstract][Full Text] [Related]
9. ALK-rearranged renal cell carcinomas in Polish population.
Gorczynski A; Czapiewski P; Korwat A; Budynko L; Prelowska M; Okon K; Biernat W
Pathol Res Pract; 2019 Dec; 215(12):152669. PubMed ID: 31677810
[TBL] [Abstract][Full Text] [Related]
10. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
Doğan K; Onder E
Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Renal Cell Carcinoma Harboring
Woo CG; Yun SJ; Son SM; Lim YH; Lee OJ
Yonsei Med J; 2020 Mar; 61(3):262-266. PubMed ID: 32102128
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.
Wang XT; Fang R; Ye SB; Zhang RS; Li R; Wang X; Ji RH; Lu ZF; Ma HH; Zhou XJ; Xia QY; Rao Q
Pathol Res Pract; 2019 Nov; 215(11):152651. PubMed ID: 31563285
[TBL] [Abstract][Full Text] [Related]
13. ALK-TPM3 rearrangement in adult renal cell carcinoma: Report of a new case showing loss of chromosome 3 and literature review.
Bodokh Y; Ambrosetti D; Kubiniek V; Tibi B; Durand M; Amiel J; Pertuit M; Barlier A; Pedeutour F
Cancer Genet; 2018 Feb; 221():31-37. PubMed ID: 29405994
[TBL] [Abstract][Full Text] [Related]
14. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
15. ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.
Hang JF; Chung HJ; Pan CC
Virchows Arch; 2020 Jun; 476(6):921-929. PubMed ID: 31993771
[TBL] [Abstract][Full Text] [Related]
16. ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report.
Kai K; Tobu S; Kido S; Mikami S; Takeuchi K; Dobashi A; Togashi Y; Noguchi M; Aishima S
Diagn Pathol; 2022 Jun; 17(1):52. PubMed ID: 35718773
[TBL] [Abstract][Full Text] [Related]
17. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
18. Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma.
Chen W; Li W; Bai B; Wei H
Oncol Rep; 2020 Mar; 43(3):817-826. PubMed ID: 32020234
[TBL] [Abstract][Full Text] [Related]
19. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
20. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
Sugawara E; Togashi Y; Kuroda N; Sakata S; Hatano S; Asaka R; Yuasa T; Yonese J; Kitagawa M; Mano H; Ishikawa Y; Takeuchi K
Cancer; 2012 Sep; 118(18):4427-36. PubMed ID: 22252991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
